Algeta
www.algeta.com
- License and collaboration agreement with the aim of developing new tumor-targeting alpha-pharmaceutical candidates based on the alpha particle emitter thorium-227.

In 2011, Algeta ASA obtained licenses to develop cancer therapeutics based on Affibody® technology for two oncology targets.

Please find more details in the press release.

Amylin
www.amylin.com
-License Agreement regarding the use of Affibody’s proprietary Albumod™ platform which is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

In 2010, Affibody signed a License Agreement regarding the use of Affibody’s proprietary Albumod™ platform. The technology will be applied on an undisclosed number of molecules from Amylin’s library of proprietary compounds.

Please find more details in the press release.

Undisclosed partner
-Agreement regarding HER2 molecular imaging

In 2010, Affibody signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.

Swedish Orphan Biovitrum
www.sobi.com
-Collaboration agreement with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.

In 2009, Affibody entered collaboration with Swedish Orphan Biovitrum (SOBi), where SOBi gains access to the proprietary technology platforms of Affibody® molecules, as well as the unique albumin-binding technology for pharmaceuticals development. The agreement consists of a defined protein target development collaboration and a product license agreement.

Please find more details in the press release.

GE Healthcare
www.gehealthcare.com
- Collaboration to develop affinity ligands for large-scale affinity purification

The product MabSelect SuRe™ was launched by GE Healthcare Bio-Sciences AB in 2004, as a result from the collaboration with Affibody for the development of affinity ligands for large-scale bioseparation.